Instrument Inactif

Communiqués Yumanity Therapeutics

Actions

YMTX

US98872L1026

Communiqués

11/05/23	Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K	PU
17/04/23	Yumanity Therapeutics : Regulation FD Presentation - Form 8-K	PU
12/04/23	Yumanity Therapeutics : VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 - Form 8-K	PU
05/01/23	Yumanity Therapeutics : January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) - Form 8-K	PU
22/12/22	Yumanity Therapeutics : Kineta Completes Reverse Merger with Yumanity Therapeutics - Form 8-K	PU
16/12/22	YUMANITY THERAPEUTICS, INC. Other Events (form 8-K/A)	AQ
15/12/22	Yumanity Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
15/12/22	YUMANITY THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/12/22	YUMANITY THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
06/12/22	YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
05/12/22	YUMANITY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
05/12/22	Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta	GL
05/12/22	Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta	GL
01/12/22	YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
30/11/22	Yumanity Therapeutics : Kineta to Participate in JMP Securities Hematology and Oncology Summit - Form 8-K	PU
29/11/22	YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
15/11/22	YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	YUMANITY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/11/22	YUMANITY THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	Yumanity: Q3 Earnings Snapshot	AQ
14/11/22	Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments	GL
14/11/22	Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments	GL
10/11/22	Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.	AQ
10/11/22	Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.	GL
26/10/22	YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ